Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Nanobiotix ( (NBTX) ) has issued an announcement.
Nanobiotix reported on March 31, 2026, that its 2025 operational progress centered on the global development of JNJ-1900 (NBTXR3), with lead head and neck and lung cancer programs advancing as planned and early-stage trials across multiple tumor types showing favorable safety and encouraging efficacy signals. During 2025, European regulators agreed to reclassify JNJ-1900 as a medicinal product, new intellectual property was filed, and key clinical milestones such as first dosing and early data from the CONVERGE lung cancer study, as well as readouts in esophageal, pancreatic, melanoma and lung re-irradiation settings, underscored the breadth of the program.
Financially, the company executed an amendment to its global licensing agreement with Janssen in early 2025 that removed most of its funding obligations for the pivotal NANORAY-312 head and neck trial and booked €32.6 million in 2025 revenue, aided by IFRS15-related effects and product and service sales to Janssen. A non-dilutive royalty financing of up to $71 million with HealthCare Royalty, of which $50 million was received in December 2025, helped extend Nanobiotix’s cash runway into early 2028, positioning it to reach major clinical milestones while progressing the Curadigm Nanoprimer platform with new patents, preclinical data and CMC activities.
The company also highlighted its growing capital markets profile through index inclusions and pointed to 2026 as a pivotal year, with multiple Phase 1 and 2 data readouts expected in non-small cell lung cancer re-irradiation, pancreatic cancer, melanoma and esophageal cancer. These developments collectively strengthen Nanobiotix’s financial and clinical foundations, enhance its standing in oncology innovation, and could have meaningful implications for partners and shareholders as the JNJ-1900 franchise and next-wave nanotherapeutics advance toward potential commercialization.
The most recent analyst rating on (NBTX) stock is a Buy with a $26.00 price target. To see the full list of analyst forecasts on Nanobiotix stock, see the NBTX Stock Forecast page.
Spark’s Take on NBTX Stock
According to Spark, TipRanks’ AI Analyst, NBTX is a Neutral.
Nanobiotix’s overall stock score is primarily impacted by its poor financial performance, with significant operational losses and financial instability. While technical analysis shows some positive momentum, the negative valuation metrics due to lack of profitability further weigh down the score.
To see Spark’s full report on NBTX stock, click here.
More about Nanobiotix
Nanobiotix S.A. is a late-clinical stage biotechnology company based in Paris and Cambridge, Mass., developing nanotherapeutic approaches to expand treatment options for cancer and other major diseases. Its lead asset, JNJ-1900 (NBTXR3), is a nanoradioenhancer designed to improve radiotherapy outcomes across solid tumors, with a market focus on large, underserved indications such as head and neck and lung cancers.
The company is also advancing its Curadigm Nanoprimer platform, aimed at optimizing the delivery and efficacy of a broad range of therapeutics and supporting both an internal pipeline and external collaborations. Nanobiotix is listed on Euronext Paris and Nasdaq and was admitted in 2025 to the CAC Mid 60 and SBF 120 indices, reinforcing its profile among mid-cap French equities.
Average Trading Volume: 44,492
Technical Sentiment Signal: Buy
Current Market Cap: $1.5B
See more insights into NBTX stock on TipRanks’ Stock Analysis page.